



May 20, 2026

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

Scrip code: 532531

Symbol: STAR

Dear Madam/ Sir,

Sub Pronouncement of Order by the Hon'ble NCLT, Bengaluru Bench regarding Scheme of Arrangement for Demerger of Demerged Undertaking of Arco Lab Private Limited, a wholly owned subsidiary of Strides Pharma Science Limited (“Company/Strides”).

Ref Intimation under Regulation 30 of the SEBI Listing Regulations

This has reference to our intimation of May 15, 2025, regarding the proposed Scheme of Arrangement for Demerger involving Arco Lab Private Limited (“Arco Lab”), wholly owned subsidiary of Strides and Pivot Path Private Limited (“Pivot Path”), wholly owned subsidiary of Arco Lab.

The Scheme provides for the demerger of Arco Lab’s Life Sciences business and Digital Innovation business (the “Demerged Undertaking”) into Pivot Path, pursuant to Sections 230–232 of the Companies Act, 2013 and other applicable provisions of the Act and the Rules framed thereunder (“Scheme”).

We wish to inform you that the aforesaid Scheme was listed for pronouncement of order before the Hon’ble National Company Law Tribunal, Bengaluru Bench (“NCLT”) on May 18, 2026, and the NCLT has approved the said Scheme. The final order approving the demerger was made available on the NCLT portal on May 20, 2026.

Arco Lab and Pivot Path are in the process of applying to the NCLT to obtain a certified copy of the said order.

Upon receipt of such certified copy, Arco Lab and Pivot Path shall file a copy of the said Order with the Registrar of Companies, pursuant to which the Scheme shall be Effective.

Effective Date of the said Scheme shall be communicated to the Stock Exchanges in due course.

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India | **Tel:** +91 80 6784 0000

Regd. Off: ‘Cyber One’, Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India

Tel: +91 22 2789 2924/3199

corpcomm@strides.com; www.strides.com



Upon Scheme becoming Effective:

- a) Pivot Path shall become a wholly owned subsidiary of Strides.
- b) Board of Directors of Arco Lab and Pivot Path shall fix Record Date for allotment of shares, basis which **Pivot Path shall allot equity shares to Strides Pharma Science Limited**, as per the share entitlement ratio provided in the Scheme.
- c) Shares of Pivot Path held by Arco Lab shall be extinguished in due course line with the Scheme.
- d) The Demerged Undertaking from Arco Lab shall vest with Pivot Path effective April 10, 2025 (**Appointed Date**).

You are requested to take the same on your record.

Thanks & regards,
For STRIDES PHARMA SCIENCE LIMITED,

Manjula Ramamurthy
Company Secretary
ICSI Membership No: A30515

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India | **Tel:** +91 80 6784 0000

Regd. Off: 'Cyber One', Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India

Tel: +91 22 2789 2924/3199

corpcomm@strides.com; www.strides.com